The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats.

The A(3) adenosine receptor (A(3)AR) is over-expressed in inflammatory cells and was defined as a target to combat inflammation. Synthetic agonists to this receptor, such as IB-MECA and Cl-IB-MECA, exert an anti-inflammatory effect in experimental animal models of adjuvant- and collagen-induced arthritis. In this study we present a novel A(3)AR agonist, CF502, with high affinity and selectivity at the human A(3)AR. CF502 induced a dose dependent inhibitory effect on the proliferation of fibroblast-like synoviocytes (FLS) via de-regulation of the nuclear factor-kappa B (NF-kappaB) signaling pathway. Furthermore, CF502 markedly suppressed the clinical and pathological manifestations of adjuvant-induced arthritis (AIA) in a rat experimental model when given orally at a low dose (100 microg/kg). As is typical of other G-protein coupled receptors, the A(3)AR expression level was down-regulated shortly after treatment with agonist CF502 in paw and in peripheral blood mononuclear cells (PBMCs) derived from treated AIA animals. Subsequently, a decrease in the expression levels of protein kinase B/Akt (PKB/Akt), IkappaB kinase (IKK), I kappa B (IkappaB), NF-kappaB and tumor necrosis factor-alpha (TNF-alpha) took place. In addition, the expression levels of glycogen synthase kinase-3 beta (GSK-3beta), beta-catenin, and poly(ADP-ribose)polymerase (PARP), known to control the level and activity of NF-kappaB, were down-regulated upon treatment with CF502. Taken together, CF502 inhibits FLS growth and the inflammatory manifestations of arthritis, supporting the development of A(3)AR agonists for the treatment of rheumatoid arthritis.

Compatibility studies between carbamazepine and tablet excipients using thermal and non-thermal methods.

Proper formulation is an important aspect of any dosage form design. As a part of preformulation studies, differential scanning calorimetry (DSC) was used to investigate the physicochemical compatibility between Carbamazepine and various excipients commonly used in tablet manufacturing, supported by Fourier transform infrared (FTIR) and x-ray powder diffraction (XRPD) studies. Compatibility studies were conducted on samples kept at room temperature and at an elevated temperature of 55 degrees C for 3 weeks. Carbamazepine was found to be compatible with all lactose-based components, such as Granulac 230, Flowlac 100, and Microcelac 100. Differential scanning calorimetry studies indicated incompatibility with mannitol, microcrystalline cellulose, starch, and stearic acid. However, XRPD and FTIR studies implied that all the above excipients are compatible with Carbamazepine. X-ray powder diffraction demonstrated incompatibility with stearic acid for samples stored at 55 degrees C for 3 weeks, indicative of formation of a solid solution. Thus, DSC being a thermal method of analysis should not be used singly to detect any inherent incompatibility. It has to be supported sufficiently by other non-thermal techniques, such as XRPD and FTIR.

Multiple ovulation and embryo transfer in Indian buffalo (Bubalus buoalis ).

This study was undertaken to identify the most effective dosage level of folltrooin for superovulation in buffalo. In addition, the effect of the day of estrus on superovulation and the use of exogenous GnRH were also studied. Eighty-three buffalo were treated with prostaglandin. A functional Corous luteum (CL) was palpated in only 73 buffalo 1 d before the superovulation treatment was initiated. One of eight treatments was used on the buffalo: Protocol I(n 8) 9 mg folltropin (PPFE) on Days 9 to 12 of the cycle; Protocol II(n 10) 18 mg PPFE on Days 9 to 12 of the cycle; Protocol III(n 9) 18 mg PPFE on Days 13 to 15 of the cycle; Protocol IV(n 9) 21.6 mg PPFE on Days 9 to 12 of the cycle; Protocol V(n 9) 21.6 mg PPFE with GnRH on Days 9 to 12 of the cycle; Protocol-VI(n 10) 25.2 mg PPFE on Days 9 to 12 of the cycle; Protocol VII(n 9) 28.8 mg PPFE on Days 9 to 12 of the cycle; Protocol VIII (n 9) 36 mg PPFE on Days 9 to 12 of the cycle. The highest ovulation rate was observed in Protocol VI (x 5.3+/-0.79) which is significantly higher (P < 0.01) than other Protocols. Maxium embryos (x 3.7) were recovered using Protocol III. Whereas, highest number of transferable embryos (x 2.2) were recovered from Protocol V. Use of GnRH and superovulation treatment on Days 13 to 15 has no advantageous effect on ovulation rate. In all, 41 embryos were transferred to 35 recioients: nine buffalo became pregnant; 59 embryos were frozen; 12 were thawed; nine good frozen-thawed embryos were transferred to eight recidients, three of which were diagnosed pregnant.